Manuel Weinheimer

Dr. Manuel Weinheimer

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PMPatricia Muschong
Patricia Muschong
KAKhader Awwad
Khader Awwad
EPEdward Price
Edward Price
MMMario Mezler
Mario Mezler
MWManuel Weinheimer
Manuel Weinheimer
Current drug development tends towards complex chemical molecules, referred to as “beyond rule of five” (bRo5) compounds, which often exhibit challenging physicochemical properties. Measuring Caco-2 permeability of those compounds is difficult due to technical limitations, including poor recovery and detection sensitivity. We implemented a novel assay, with optimized incubation and analytics, to measure permeability close to equilibrium. In this setup an appropriate characterization of permeability for bRo5 compounds is achievable. This equilibrated Caco-2 assay was verified with respect to data validity, compound recovery, and in vitro to in vivo correlation for human absorption. Compared to a standard assay, it demonstrated comparable performance in predicting the human fraction absorbed (fa) for reference compounds. The equilibrated assay also successfully characterized the permeability of more than 90% of the compounds analyzed, the majority of which were bRo5 (68%). These compounds could not be measured using the standard assay. Permeability and efflux ratio (ER) were highly predictive for in vivo absorption for a large set of internal bRo5 compounds. Reference cut-offs enabled the correct classification of high, moderate, and low absorption. This optimized equilibrated Caco-2 assay closes the gap for a high-throughput cellular permeability method in the bRo5 chemical space.

24 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DYDong Ye
Dong Ye
ÁMÁlvaro López Mármol
Álvaro López Mármol
VLVerena Lenz
Verena Lenz
PMPatricia Muschong
Patricia Muschong
AWAnita Wilhelm-Alkubaisi
Anita Wilhelm-Alkubaisi
MMMario Mezler
Mario Mezler
The poor solubility and permeability of compounds beyond Lipinski’s Rule of Five (bRo5) are major challenges for cell-based permeability assays. Due to their incompatibility with gastrointestinal components in biorelevant media, the exploration of important questions addressing food effects is limited. Thus, we established a robust mucin-protected Caco-2 assay to allow the assessment of drug permeation in complex biorelevant media. To do that, the assay conditions were first optimized with dependence of the concentration of porcine mucin added to the cells. Mucin-specific effects on drug permeability were evaluated by analyzing cell permeability values for 15 reference drugs (BCS class I–IV). Secondly, a sigmoidal relationship between mucin-dependent permeability and fraction absorbed in human (fa) was established. A case study with venetoclax (BCS class IV) was performed to investigate the impact of medium complexity and the prandial state on drug permeation. Luminal fluids obtained from the tiny-TIM system showed a higher solubilization capacity for venetoclax, and a better read-out for the drug permeability, as compared to FaSSIF or FeSSIF media. In conclusion, the mucin-protected Caco-2 assay combined with biorelevant media improves the mechanistic understanding of drug permeation and addresses complex biopharmaceutical questions, such as food effects on oral drug absorption.

28 March 2023 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
PMPatricia Muschong
Patricia Muschong
LJLiang Jin
Liang Jin
JSJan Schejbal
Jan Schejbal
MMMario Mezler
Mario Mezler
MWManuel Weinheimer
Manuel Weinheimer

19 December 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
EPEdward Price
Edward Price
VSVirginia Saulnier
Virginia Saulnier
JKJohn Cory Kalvass
John Cory Kalvass
SDStella Doktor
Stella Doktor
MWManuel Weinheimer
Manuel Weinheimer
GJGary Jenkins
Gary Jenkins
Biopharmaceutical companies generate a wealth of data, ranging from in silico physicochemical properties and machine learning models to both low and high-throughput in vitro assays and in vivo studies. To effectively harnesses this extensive data, we introduce a statistical methodology facilitated by Accuracy, Utility, and Rank Order Assessment (AURA), which combines basic statistical analyses with dynamic data visualizations to evaluate endpoint effectiveness in predicting intestinal absorption. We demonstrated that various physicochemical properties uniquely influence intestinal absorption on a project-specific basis, considering factors like intestinal efflux, passive permeability, and clearance. Projects within both the "Rule of 5" (Ro5) and beyond "Rule of 5" (bRo5) space present unique absorption challenges, emphasizing the need for tailored optimization strategies over one-size-fits-all approaches. This is corroborated by the improved accuracy of project-specific correlations over global models. The differences in correlations between and within project teams-due to their unique chemical spaces-highlight how complex and nuanced the prediction of intestinal absorption can be. Here, we implement a standardized methodology, AURA, that any organization can incorporate into their workflow to enhance early-stage drug optimization. By automating analytics, integrating diverse data types, and offering flexible visualizations, AURA enables cross-functional teams to make data-driven decisions, optimize workflows, and enhance research efficiency.

18 April 2023 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
PMPatricia Muschong
Patricia Muschong
LJLiang Jin
Liang Jin
JSJan Schejbal
Jan Schejbal
MMMario Mezler
Mario Mezler
MWManuel Weinheimer
Manuel Weinheimer